Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

NCT02802943 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT02802943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02802943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Completed
Start date
October 5, 2016
Completion date
November 18, 2022
Enrollment
56 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, chronic lymphatic